Generation Bio
Cambridge
About Generation Bio
Generation Bio is an innovative genetic medicines company focused on creating a new class of gene therapy to provide durable, redosable treatments for patients suffering from both rare and prevalent diseases. The company’s non-viral platform incorporates a proprietary high-capacity DNA construct called closed-ended DNA, or ceDNA; a novel cell-targeted lipid nanoparticle delivery system, or ctLNP; and an established, scalable capsid-free manufacturing process. The company is designing therapies to provide targeted delivery of genetic payloads that include large and multiple genes across a broad array of tissues, and to be redosable for individualized and extended treatment throughout a patient’s life. The platform is designed to expand access to treatments for rare diseases and to address prevalent diseases through efficient, scalable manufacturing.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 101 – 250
- Estimated revenue: $10K – $50K
- Total funding: $536.4M
- Funding stage: M&A
- Last round: Post-IPO Equity (Mar 2023)
- Ticker: nasdaq:GBIO
- Website: generationbio.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Genetics, Health Care
Social Profiles
Canonical: https://fsome.com/organization/generation-bio-72420 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.